Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

Phase 3VAX-31Neutral

AI Analysis

Summary

Vaxcyte announced it will present topline data from the OPUS-1 pivotal Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, on October 5, 2026. The trial evaluated the safety, tolerability, and immunogenicity of VAX-31 for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Topline data from OPUS-1 pivotal adult Phase 3 trial to be presented

Importance:7/10

Sentiment:

0.00

pneumococcal vaccinePhase 3VAX-31OPUS-1immunogenicityPCV

Related Companies

$PCVX

Read the original article

Published by GlobeNewswire Clinical Studies on October 4, 2026 9:00 PM

Read Original